Compare Enveric Biosciences Inc (ENVB) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ProShares Ultra QQQ ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while ProShares Ultra QQQ ETF trades at $99.2 (market cap $15.83B). The key difference: ProShares Ultra QQQ ETF is far larger — about 2366.2× Enveric Biosciences Inc's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and ProShares Ultra QQQ ETF for 37 Days on average.
| ENVB | QLD | |
|---|---|---|
Market Cap | $6.69M | $15.83B |
Volume | 41,141 | 3,097,438 |
Sector | Health | Leveraged / Inverse |
52-Week High | $10.80 | $100.77 |
52-Week Low | $1.27 | $57.16 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
QLD (ProShares Ultra QQQ ETF) trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, offering amplified returns during market rallies while being less volatile than 3x leveraged alternatives. Recent institutional buying activity and media coverage highlight continued investor interest in leveraged tech exposure.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $99 and resistance at $101. While the bullish moving average alignment suggests upward momentum, overbought RSI levels indicate potential near-term consolidation. Key risks include market volatility, Federal Reserve policy impacts, and the inherent leverage decay characteristic of daily reset ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
